Fanny Collaud

Fanny Collaud

Auto-generated profile, based on publicly available information

Fanny Collaud

Généthon, 91000 Évry, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CLChristian Leborgne
Christian Leborgne
EBElena Barbon
Elena Barbon
JAJeffrey M. Alexander
Jeffrey M. Alexander
HHHayley Hanby
Hayley Hanby
SDSandrine Delignat
Sandrine Delignat
FMFederico Mingozzi
Federico Mingozzi

5 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
AMAmine Meliani
Amine Meliani
FBFlorence Boisgerault
Florence Boisgerault
RHRomain Hardet
Romain Hardet
SMSolenne Marmier
Solenne Marmier
FCFanny Collaud
Fanny Collaud
FMFederico Mingozzi
Federico Mingozzi
Gene therapy mediated by recombinant adeno-associated virus (AAV) vectors is a promising treatment for systemic monogenic diseases. However, vector immunogenicity represents a major limitation to gene transfer with AAV vectors, particularly for vector re-administration. Here, we demonstrate that synthetic vaccine particles encapsulating rapamycin (SVP[Rapa]), co-administered with AAV vectors, prevents the induction of anti-capsid humoral and cell-mediated responses. This allows successful vector re-administration in mice and nonhuman primates. SVP[Rapa] dosed with AAV vectors reduces B and T cell activation in an antigen-selective manner, inhibits CD8+ T cell infiltration in the liver, and efficiently blocks memory T cell responses. SVP[Rapa] immunomodulatory effects can be transferred from treated to naive mice by adoptive transfer of splenocytes, and is inhibited by depletion of CD25+ T cells, suggesting a role for regulatory T cells. Co-administration of SVP[Rapa] with AAV vector represents a powerful strategy to modulate vector immunogenicity and enable effective vector re-administration.

1 June 2018 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
ZFZachary Fitzpatrick
Zachary Fitzpatrick
CLChristian Leborgne
Christian Leborgne
EBElena Barbon
Elena Barbon
EMElisa Masat
Elisa Masat
GRGiuseppe Ronzitti
Giuseppe Ronzitti
FMFederico Mingozzi
Federico Mingozzi
Pre-existing immunity to adeno-associated virus (AAV) is highly prevalent in humans and can profoundly impact transduction efficiency. Despite the relevance to AAV-mediated gene transfer, relatively little is known about the fate of AAV vectors in the presence of neutralizing antibodies (NAbs). Similarly, the effect of binding antibodies (BAbs), with no detectable neutralizing activity, on AAV transduction is ill defined. Here, we delivered AAV8 vectors to mice carrying NAbs and demonstrated that AAV particles are taken up by both liver parenchymal and non-parenchymal cells; viral particles are then rapidly cleared, without resulting in transgene expression. In vitro, imaging of hepatocytes exposed to AAV vectors pre-incubated with either NAbs or BAbs revealed that virus is taken up by cells in both cases. Whereas no successful transduction was observed when AAV was pre-incubated with NAbs, an increased capsid internalization and transgene expression was observed in the presence of BAbs. Accordingly, AAV8 vectors administered to mice passively immunized with anti-AAV8 BAbs showed a more efficient liver transduction and a unique vector biodistribution profile compared to mice immunized with NAbs. These results highlight a virtually opposite effect of neutralizing and binding antibodies on AAV vectors transduction.

16 October 2017 in Blood Advances
Verified
Journal Article
Closed access
PDF file
AMAmine Meliani
Amine Meliani
FBFlorence Boisgerault
Florence Boisgerault
ZFZachary Fitzpatrick
Zachary Fitzpatrick
SMSolenne Marmier
Solenne Marmier
CLChristian Leborgne
Christian Leborgne
FMFederico Mingozzi
Federico Mingozzi
Results from clinical trials of liver gene transfer for hemophilia demonstrate the potential of the adeno-associated virus (AAV) vector platform. However, to achieve therapeutic transgene expression, in some cases high vector doses are required, which are associated with a higher risk of triggering anti-capsid cytotoxic T-cell responses. Additionally, anti-AAV preexisting immunity can prevent liver transduction even at low neutralizing antibody (NAb) titers. Here, we describe the use of exosome-associated AAV (exo-AAV) vectors as a robust liver gene delivery system that allows the therapeutic vector dose to be decreased while protecting from preexisting humoral immunity to the capsid. The in vivo efficiency of liver targeting of standard AAV8 or AAV5 and exo-AAV8 or exo-AAV5 vectors expressing human coagulation factor IX (hF.IX) was evaluated. A significant enhancement of transduction efficiency was observed, and in hemophilia B mice treated with 4 × 1010 vector genomes per kilogram of exo-AAV8 vectors, a staggering ∼1 log increase in hF.IX transgene expression was observed, leading to superior correction of clotting time. Enhanced liver expression was also associated with an increase in the frequency of regulatory T cells in lymph nodes. The efficiency of exo- and standard AAV8 vectors in evading preexisting NAbs to the capsid was then evaluated in a passive immunization mouse model and in human sera. Exo-AAV8 gene delivery allowed for efficient transduction even in the presence of moderate NAb titers, thus potentially extending the proportion of subjects eligible for liver gene transfer. Exo-AAV vectors therefore represent a platform to improve the safety and efficacy of liver-directed gene transfer. Key Points Enveloped AAV vectors are able to transduce the liver highly efficiently, driving superior correction of hemophilia B in mice. Enveloped AAVs are less susceptible to antibody-mediated neutralization, allowing for liver transduction in preimmunized animals. Visual Abstract

29 November 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
FPFrancesco Puzzo
Francesco Puzzo
PCPasqualina Colella
Pasqualina Colella
MBMaria Grazia Biferi
Maria Grazia Biferi
DBDeeksha Bali
Deeksha Bali
NPNicole K. Paulk
Nicole K. Paulk
FMFederico Mingozzi
Federico Mingozzi
Liver delivery of engineered GAA transgenes to mice with Pompe disease rescued glycogen accumulation in multiple tissues.

22 October 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KKKlaudia Kuranda
Klaudia Kuranda
PJPriscilla Jean-Alphonse
Priscilla Jean-Alphonse
CLChristian Leborgne
Christian Leborgne
RHRomain Hardet
Romain Hardet
FCFanny Collaud
Fanny Collaud
FMFederico Mingozzi
Federico Mingozzi
Recombinant adeno-associated virus (AAV) vectors have been broadly adopted as a gene delivery tool in clinical trials, owing to their high efficiency of transduction of several host tissues and their low immunogenicity. However, a considerable proportion of the population is naturally exposed to the WT virus from which AAV vectors are derived, which leads to the acquisition of immunological memory that can directly determine the outcome of gene transfer. Here, we show that prior exposure to AAV drives distinct capsid immunity profiles in healthy subjects. In peripheral blood mononuclear cells (PBMCs) isolated from AAV-seropositive donors, recombinant AAV triggered TNF-α secretion in memory CD8+ T cells, B cell differentiation into antibody-secreting cells, and anti-capsid antibody production. Conversely, PBMCs isolated from AAV-seronegative individuals appeared to carry a population of NK cells reactive to AAV. Further, we demonstrated that the AAV capsid activates IL-1β and IL-6 cytokine secretion in monocyte-related dendritic cells (moDCs). IL-1β and IL-6 blockade inhibited the anti-capsid humoral response in vitro and in vivo. These results provide insights into immune responses to AAV in humans, define a possible role for moDCs and NK cells in capsid immunity, and open new avenues for the modulation of vector immunogenicity.